{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:09:41Z","timestamp":1762999781774,"version":"3.40.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00392-022-02123-x","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:11:04Z","timestamp":1667495464000},"page":"158-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Defining the gap in heart failure treatment in patients with cardiac implantable electronic devices"],"prefix":"10.1007","volume":"112","author":[{"given":"Samaneh","family":"Salimian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc W.","family":"Deyell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean A.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason G.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-2014","authenticated-orcid":false,"given":"Nathaniel M.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"issue":"2","key":"2123_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/CIRCOUTCOMES.109.880450","volume":"3","author":"PJ Hauptman","year":"2010","unstructured":"Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE (2010) Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Circ Cardiovasc Qual Outcomes 3(2):204\u2013211. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.109.880450","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"2123_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","volume":"67","author":"GA Roth","year":"2016","unstructured":"Roth GA, Poole JE, Zaha R, Zhou W, Skinner J, Morden NE (2016) Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation. J Am Coll Cardiol 67(9):1062\u20131069. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.046","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2123_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ehjcvp\/pvv016","volume":"1","author":"CT Witt","year":"2015","unstructured":"Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC (2015) Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. Eur Heart J Cardiovasc Pharmacother 1(3):182\u2013188. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"2123_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cardfail.2017.03.001","volume":"23","author":"P Martens","year":"2017","unstructured":"Martens P, Verbrugge FH, Nijst P, Bertrand PB, Dupont M, Tang WH et al (2017) Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy. J Card Fail 23(8):597\u2013605. https:\/\/doi.org\/10.1016\/j.cardfail.2017.03.001","journal-title":"J Card Fail"},{"issue":"1","key":"2123_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/00015385.2018.1547469","volume":"75","author":"P Martens","year":"2020","unstructured":"Martens P, Dupont M, Mullens W (2020) Reduced occurrence of appropriate therapy for ventricular arrhythmias after beta-blocker uptitration following implant of a primary prevention CRT-defibrillator. Acta Cardiol 75(1):49\u201353. https:\/\/doi.org\/10.1080\/00015385.2018.1547469","journal-title":"Acta Cardiol"},{"issue":"6","key":"2123_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.hroo.2021.09.010","volume":"2","author":"S Salimian","year":"2021","unstructured":"Salimian S, Deyell MW, Andrade JG, Chakrabarti S, Bennett MT, Krahn AD et al (2021) Heart failure treatment in patients with cardiac implantable electronic devices: opportunity for improvement. Heart Rhythm O2. 2(6):698\u2013709","journal-title":"Heart Rhythm O2."},{"issue":"5","key":"2123_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00392-019-01553-4","volume":"109","author":"A Jorsal","year":"2020","unstructured":"Jorsal A, Pryds K, McMurray JJV, Wiggers H, Sommer A, Nielsen JC et al (2020) Optimizing heart failure treatment following cardiac resynchronization therapy. Clin Res Cardiol 109(5):638\u2013645. https:\/\/doi.org\/10.1007\/s00392-019-01553-4","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"2123_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al (2021) CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37(4):531\u2013546. https:\/\/doi.org\/10.1016\/j.cjca.2021.01.017","journal-title":"Can J Cardiol"},{"issue":"6","key":"2123_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL et al (2021) 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol 77(6):772\u2013810. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.022","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2123_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1161\/CIRCULATIONAHA.117.027773","volume":"135","author":"KS Parikh","year":"2017","unstructured":"Parikh KS, Lippmann SJ, Greiner M, Heidenreich PA, Yancy CW, Fonarow GC et al (2017) Scope of sacubitril\/valsartan eligibility after heart failure hospitalization: findings from the GWTG-HF Registry (Get With The Guidelines-Heart Failure). Circulation 135(21):2077\u20132080","journal-title":"Circulation"},{"issue":"3","key":"2123_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","volume":"52","author":"GC Fonarow","year":"2008","unstructured":"Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH et al (2008) Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52(3):190\u2013199","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2123_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamacardio.2020.5864","volume":"6","author":"M Vaduganathan","year":"2021","unstructured":"Vaduganathan M, Greene SJ, Zhang S, Grau-Sepulveda M, DeVore AD, Butler J et al (2021) Applicability of US food and drug administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in us clinical practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. JAMA cardiol 6(3):267\u2013275","journal-title":"JAMA cardiol"},{"issue":"4","key":"2123_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72(4):351\u2013366","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2123_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005400","volume":"11","author":"AD DeVore","year":"2018","unstructured":"DeVore AD, Hill CL, Thomas L, Sharma PP, Albert NM, Butler J et al (2018) Patient, provider, and practice characteristics associated with sacubitril\/valsartan use in the United States. Circ Heart Fail 11(9):e005400. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005400","journal-title":"Circ Heart Fail"},{"issue":"5","key":"2123_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","volume":"3","author":"JT Heywood","year":"2010","unstructured":"Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gheorghiade M et al (2010) Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail 3(5):596\u2013605. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.912683","journal-title":"Circ Heart Fail"},{"issue":"12","key":"2123_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ejhf.2046","volume":"22","author":"W Mullens","year":"2020","unstructured":"Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V et al (2020) Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J of Heart Fail 22(12):2349\u20132369","journal-title":"Eur J of Heart Fail"},{"key":"2123_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijcard.2017.02.015","volume":"236","author":"A D'Onofrio","year":"2017","unstructured":"D\u2019Onofrio A, Palmisano P, Rapacciuolo A, Ammendola E, Calo L, Ruocco A et al (2017) Effectiveness of a management program for outpatient clinic or remote titration of beta-blockers in CRT patients: The RESTORE study. Int J Cardiol 236:290\u2013295. https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.015","journal-title":"Int J Cardiol"},{"issue":"21","key":"2123_CR18","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"M Bristow","year":"2004","unstructured":"Bristow M, Saxon L, Boehmer J, Krueger S, Kass D, De MT et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140\u20132150","journal-title":"N Engl J Med"},{"issue":"15","key":"2123_CR19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539\u20131549","journal-title":"N Engl J Med"},{"issue":"9","key":"2123_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GM, Dahlstr\u00f6m U et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20(9):1326\u20131334","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2123_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.amjcard.2004.12.023","volume":"95","author":"JM Aranda Jr","year":"2005","unstructured":"Aranda JM Jr, Woo GW, Conti JB, Schofield RS, Conti CR, Hill JA (2005) Use of cardiac resynchronization therapy to optimize beta-blocker therapy in patients with heart failure and prolonged QRS duration. Am J Cardiol 95(7):889\u2013891. https:\/\/doi.org\/10.1016\/j.amjcard.2004.12.023","journal-title":"Am J Cardiol"},{"issue":"12","key":"2123_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1365-2362.2009.02217.x","volume":"39","author":"C Adlbrecht","year":"2009","unstructured":"Adlbrecht C, Hulsmann M, Gwechenberger M, Strunk G, Khazen C, Wiesbauer F et al (2009) Outcome after device implantation in chronic heart failure is dependent on concomitant medical treatment. Eur J Clin Invest 39(12):1073\u20131081. https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02217.x","journal-title":"Eur J Clin Invest"},{"issue":"16","key":"2123_CR23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/eurheartj\/eht514","volume":"35","author":"S Schmidt","year":"2014","unstructured":"Schmidt S, Hurlimann D, Starck CT, Hindricks G, Luscher TF, Ruschitzka F et al (2014) Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J 35(16):1051\u20131060. https:\/\/doi.org\/10.1093\/eurheartj\/eht514","journal-title":"Eur Heart J"},{"issue":"11","key":"2123_CR24","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.amjcard.2012.01.387","volume":"109","author":"L Mantziari","year":"2012","unstructured":"Mantziari L, Guha K, Khalique Z, McDonagh T, Sharma R (2012) Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis. Am J Cardiol 109(11):1619\u20131625. https:\/\/doi.org\/10.1016\/j.amjcard.2012.01.387","journal-title":"Am J Cardiol"},{"issue":"36","key":"2123_CR25","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"11","key":"2123_CR26","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jacc.2021.02.006","volume":"77","author":"SJ Greene","year":"2021","unstructured":"Greene SJ, Khan MS (2021) Quadruple medical therapy for heart failure: medications working together to provide the best care. J Am Coll Cardiol 77(11):1408\u20131411","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2123_CR27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ejhf.2259","volume":"23","author":"AS Bhatt","year":"2021","unstructured":"Bhatt AS, Vaduganathan M, Claggett BL, Liu J, Packer M, Desai AS et al (2021) Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail 23(9):1518\u20131524","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2123_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2021) Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol 77(11):1397\u20131407","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2123_CR29","first-page":"188","volume":"8","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P et al (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. Heart Fail 8(3):188\u2013198","journal-title":"Heart Fail"},{"issue":"36","key":"2123_CR30","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","volume":"41","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, B\u00f6hm M, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 41(36):3402\u20133418","journal-title":"Eur Heart J"},{"issue":"3","key":"2123_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jchf.2016.12.011","volume":"5","author":"JP Boehmer","year":"2017","unstructured":"Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A et al (2017) A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Failure 5(3):216\u2013225. https:\/\/doi.org\/10.1016\/j.jchf.2016.12.011","journal-title":"JACC Heart Failure"},{"issue":"3","key":"2123_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.hfc.2015.03.009","volume":"11","author":"O Wever-Pinzon","year":"2015","unstructured":"Wever-Pinzon O, Drakos SG, Fang JC (2015) Team-based care for advanced heart failure. Heart Fail Clin 11(3):467\u2013477","journal-title":"Heart Fail Clin"},{"issue":"18","key":"2123_CR33","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJM199511023331806","volume":"333","author":"MW Rich","year":"1995","unstructured":"Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM (1995) A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333(18):1190\u20131195","journal-title":"N Engl J Med"},{"issue":"11","key":"2123_CR34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/ejhf.838","volume":"19","author":"S Zaman","year":"2017","unstructured":"Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP et al (2017) The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 19(11):1401\u20131409. https:\/\/doi.org\/10.1002\/ejhf.838","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2123_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","volume":"8","author":"M Jarjour","year":"2020","unstructured":"Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A et al (2020) Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations? JACC Heart Failure 8(9):725\u2013738. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.019","journal-title":"JACC Heart Failure"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02123-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T16:05:10Z","timestamp":1674057910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02123-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2123"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02123-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"type":"print","value":"1861-0684"},{"type":"electronic","value":"1861-0692"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"assertion":[{"value":"3 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: JA received grants and personal fees from Medtronic, Bayer, BMS-Pfizer, Servier; grants from Baylis; personal fees from Biosense-Webster. SS received salary support for quality improvement from Novartis, MD received grants and personal fees from Biosense Webster, personal fees from Medtronic, Bayer, BMS-Pfizer and Abbott, and NH received speakers\u2019 fees from Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"After discussion with the Research Ethics Board the study was exempted from further review since quality improvement activities are exempt under article 2.5 of TCPS2, the overarching ethical framework for research involving human participants in Canada.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}